Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
Abstract Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein sequences segregate into two distinct subfamilies, designated A and B. Here, we report the specificity and...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2010-08, Vol.28 (37), p.6086-6093 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6093 |
|---|---|
| container_issue | 37 |
| container_start_page | 6086 |
| container_title | Vaccine |
| container_volume | 28 |
| creator | Jiang, Han-Qing Hoiseth, Susan K Harris, Shannon L McNeil, Lisa K Zhu, Duzhang Tan, Cuiwen Scott, Adrienne A Alexander, Kristin Mason, Kathryn Miller, Lynn DaSilva, Ida Mack, Michelle Zhao, Xiao-Juan Pride, Michael W Andrew, Lubomira Murphy, Ellen Hagen, Michael French, Roger Arora, Ashoni Jones, Thomas R Jansen, Kathrin U Zlotnick, Gary W Anderson, Annaliesa S |
| description | Abstract Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein sequences segregate into two distinct subfamilies, designated A and B. Here, we report the specificity and vaccine potential of mono- or bivalent fHBP-containing vaccines. A bivalent fHBP vaccine composed of a member of each subfamily elicited substantially broader bactericidal activity against MnB strains expressing heterologous fHBP than did either of the monovalent vaccines. Bivalent rabbit immune sera tested in serum bactericidal antibody assays (SBAs) against a diverse panel of MnB clinical isolates killed 87 of the 100 isolates. Bivalent human immune sera killed 36 of 45 MnB isolates tested in SBAs. Factors such as fHBP protein variant, PorA subtype, or MLST were not predictive of whether the MnB strain could be killed by rabbit or human immune sera. Instead, the best predictor for killing in the SBA was the level of in vitro surface expression of fHBP. The bivalent fHBP vaccine candidate induced immune sera that killed MnB isolates representing the major MLST complexes, prevalent PorA subtypes, and fHBP variants that span the breadth of the fHBP phylogenetic tree. Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed. |
| doi_str_mv | 10.1016/j.vaccine.2010.06.083 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_807267085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X10009242</els_id><sourcerecordid>807267085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-c6e8b4b3a6506112e14e186bb58530e31b6788233c6434a637ae45be5f5c35c23</originalsourceid><addsrcrecordid>eNqFksGKFDEQhhtR3HX1EZSAiKcZK0kn6b64uIu6woIHFbyFdLp6yNiTjEnPwD6Fr2w1Mzqwlz0lJN__J1V_VdVLDksOXL9bL_fO-xBxKYDOQC-hkY-qc94YuRCKN4-rcxC6XtQcfp5Vz0pZA4CSvH1anQnQvJVGn1d_rnJyPTt6MZ_2mN0K2TZjH_yEPRtSZo51Ye9GjBPL6NOmC9HRfnB-otsbuo19iCtSpQlDZJ0reDKd0my3n9UFc1rltNuyK7bBSJrkk_duZH0oSKrn1ZPBjQVfHNeL6senj9-vbxa3Xz9_uf5wu_AK2mnhNTZd3UmnFZXCBfIaeaO7TjVKAkreadM0Qkqva1k7LY3DWnWoBuWl8kJeVG8PvvTl3zssk92E4nEcXcS0K7YBI7QBcnuINHXTGgDDiXx9j1ynXY5UhuV1a4QwIA1R6kD5nErJONhtDhuX7ywHO0dr1_bYOTtHa0FbipZ0r47uu26D_X_VvywJeHMEXKGODtlFH8qJk4JLrVriLg8cUn_3AbMtPmD0FDiFO9k-hQe_8v6egx9DDPToL7zDcqraFmHBfpvncB5DThPYilrIv29m2cc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1497227037</pqid></control><display><type>article</type><title>Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jiang, Han-Qing ; Hoiseth, Susan K ; Harris, Shannon L ; McNeil, Lisa K ; Zhu, Duzhang ; Tan, Cuiwen ; Scott, Adrienne A ; Alexander, Kristin ; Mason, Kathryn ; Miller, Lynn ; DaSilva, Ida ; Mack, Michelle ; Zhao, Xiao-Juan ; Pride, Michael W ; Andrew, Lubomira ; Murphy, Ellen ; Hagen, Michael ; French, Roger ; Arora, Ashoni ; Jones, Thomas R ; Jansen, Kathrin U ; Zlotnick, Gary W ; Anderson, Annaliesa S</creator><creatorcontrib>Jiang, Han-Qing ; Hoiseth, Susan K ; Harris, Shannon L ; McNeil, Lisa K ; Zhu, Duzhang ; Tan, Cuiwen ; Scott, Adrienne A ; Alexander, Kristin ; Mason, Kathryn ; Miller, Lynn ; DaSilva, Ida ; Mack, Michelle ; Zhao, Xiao-Juan ; Pride, Michael W ; Andrew, Lubomira ; Murphy, Ellen ; Hagen, Michael ; French, Roger ; Arora, Ashoni ; Jones, Thomas R ; Jansen, Kathrin U ; Zlotnick, Gary W ; Anderson, Annaliesa S</creatorcontrib><description>Abstract Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein sequences segregate into two distinct subfamilies, designated A and B. Here, we report the specificity and vaccine potential of mono- or bivalent fHBP-containing vaccines. A bivalent fHBP vaccine composed of a member of each subfamily elicited substantially broader bactericidal activity against MnB strains expressing heterologous fHBP than did either of the monovalent vaccines. Bivalent rabbit immune sera tested in serum bactericidal antibody assays (SBAs) against a diverse panel of MnB clinical isolates killed 87 of the 100 isolates. Bivalent human immune sera killed 36 of 45 MnB isolates tested in SBAs. Factors such as fHBP protein variant, PorA subtype, or MLST were not predictive of whether the MnB strain could be killed by rabbit or human immune sera. Instead, the best predictor for killing in the SBA was the level of in vitro surface expression of fHBP. The bivalent fHBP vaccine candidate induced immune sera that killed MnB isolates representing the major MLST complexes, prevalent PorA subtypes, and fHBP variants that span the breadth of the fHBP phylogenetic tree. Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2010.06.083</identifier><identifier>PMID: 20619376</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Animals ; Antibodies ; Antigens, Bacterial - immunology ; Applied microbiology ; Bacterial Proteins - immunology ; Biological and medical sciences ; Colleges & universities ; Female ; fHBP ; Fundamental and applied biological sciences. Psychology ; Humans ; LP2086 ; Meningitis ; Meningococcal Infections - immunology ; Meningococcal Infections - prevention & control ; Meningococcal Vaccines - immunology ; Microbiology ; Mortality ; N. meningitidis serogroup B ; Neisseria meningitidis ; Neisseria meningitidis, Serogroup B - genetics ; Neisseria meningitidis, Serogroup B - immunology ; Proteins ; Public health ; Rabbits ; Recombinant Proteins - immunology ; Serum Bactericidal Test ; Species Specificity ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><ispartof>Vaccine, 2010-08, Vol.28 (37), p.6086-6093</ispartof><rights>Elsevier Ltd</rights><rights>2010 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Aug 23, 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-c6e8b4b3a6506112e14e186bb58530e31b6788233c6434a637ae45be5f5c35c23</citedby><cites>FETCH-LOGICAL-c509t-c6e8b4b3a6506112e14e186bb58530e31b6788233c6434a637ae45be5f5c35c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X10009242$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23213659$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20619376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiang, Han-Qing</creatorcontrib><creatorcontrib>Hoiseth, Susan K</creatorcontrib><creatorcontrib>Harris, Shannon L</creatorcontrib><creatorcontrib>McNeil, Lisa K</creatorcontrib><creatorcontrib>Zhu, Duzhang</creatorcontrib><creatorcontrib>Tan, Cuiwen</creatorcontrib><creatorcontrib>Scott, Adrienne A</creatorcontrib><creatorcontrib>Alexander, Kristin</creatorcontrib><creatorcontrib>Mason, Kathryn</creatorcontrib><creatorcontrib>Miller, Lynn</creatorcontrib><creatorcontrib>DaSilva, Ida</creatorcontrib><creatorcontrib>Mack, Michelle</creatorcontrib><creatorcontrib>Zhao, Xiao-Juan</creatorcontrib><creatorcontrib>Pride, Michael W</creatorcontrib><creatorcontrib>Andrew, Lubomira</creatorcontrib><creatorcontrib>Murphy, Ellen</creatorcontrib><creatorcontrib>Hagen, Michael</creatorcontrib><creatorcontrib>French, Roger</creatorcontrib><creatorcontrib>Arora, Ashoni</creatorcontrib><creatorcontrib>Jones, Thomas R</creatorcontrib><creatorcontrib>Jansen, Kathrin U</creatorcontrib><creatorcontrib>Zlotnick, Gary W</creatorcontrib><creatorcontrib>Anderson, Annaliesa S</creatorcontrib><title>Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein sequences segregate into two distinct subfamilies, designated A and B. Here, we report the specificity and vaccine potential of mono- or bivalent fHBP-containing vaccines. A bivalent fHBP vaccine composed of a member of each subfamily elicited substantially broader bactericidal activity against MnB strains expressing heterologous fHBP than did either of the monovalent vaccines. Bivalent rabbit immune sera tested in serum bactericidal antibody assays (SBAs) against a diverse panel of MnB clinical isolates killed 87 of the 100 isolates. Bivalent human immune sera killed 36 of 45 MnB isolates tested in SBAs. Factors such as fHBP protein variant, PorA subtype, or MLST were not predictive of whether the MnB strain could be killed by rabbit or human immune sera. Instead, the best predictor for killing in the SBA was the level of in vitro surface expression of fHBP. The bivalent fHBP vaccine candidate induced immune sera that killed MnB isolates representing the major MLST complexes, prevalent PorA subtypes, and fHBP variants that span the breadth of the fHBP phylogenetic tree. Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antigens, Bacterial - immunology</subject><subject>Applied microbiology</subject><subject>Bacterial Proteins - immunology</subject><subject>Biological and medical sciences</subject><subject>Colleges & universities</subject><subject>Female</subject><subject>fHBP</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>LP2086</subject><subject>Meningitis</subject><subject>Meningococcal Infections - immunology</subject><subject>Meningococcal Infections - prevention & control</subject><subject>Meningococcal Vaccines - immunology</subject><subject>Microbiology</subject><subject>Mortality</subject><subject>N. meningitidis serogroup B</subject><subject>Neisseria meningitidis</subject><subject>Neisseria meningitidis, Serogroup B - genetics</subject><subject>Neisseria meningitidis, Serogroup B - immunology</subject><subject>Proteins</subject><subject>Public health</subject><subject>Rabbits</subject><subject>Recombinant Proteins - immunology</subject><subject>Serum Bactericidal Test</subject><subject>Species Specificity</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFksGKFDEQhhtR3HX1EZSAiKcZK0kn6b64uIu6woIHFbyFdLp6yNiTjEnPwD6Fr2w1Mzqwlz0lJN__J1V_VdVLDksOXL9bL_fO-xBxKYDOQC-hkY-qc94YuRCKN4-rcxC6XtQcfp5Vz0pZA4CSvH1anQnQvJVGn1d_rnJyPTt6MZ_2mN0K2TZjH_yEPRtSZo51Ye9GjBPL6NOmC9HRfnB-otsbuo19iCtSpQlDZJ0reDKd0my3n9UFc1rltNuyK7bBSJrkk_duZH0oSKrn1ZPBjQVfHNeL6senj9-vbxa3Xz9_uf5wu_AK2mnhNTZd3UmnFZXCBfIaeaO7TjVKAkreadM0Qkqva1k7LY3DWnWoBuWl8kJeVG8PvvTl3zssk92E4nEcXcS0K7YBI7QBcnuINHXTGgDDiXx9j1ynXY5UhuV1a4QwIA1R6kD5nErJONhtDhuX7ywHO0dr1_bYOTtHa0FbipZ0r47uu26D_X_VvywJeHMEXKGODtlFH8qJk4JLrVriLg8cUn_3AbMtPmD0FDiFO9k-hQe_8v6egx9DDPToL7zDcqraFmHBfpvncB5DThPYilrIv29m2cc</recordid><startdate>20100823</startdate><enddate>20100823</enddate><creator>Jiang, Han-Qing</creator><creator>Hoiseth, Susan K</creator><creator>Harris, Shannon L</creator><creator>McNeil, Lisa K</creator><creator>Zhu, Duzhang</creator><creator>Tan, Cuiwen</creator><creator>Scott, Adrienne A</creator><creator>Alexander, Kristin</creator><creator>Mason, Kathryn</creator><creator>Miller, Lynn</creator><creator>DaSilva, Ida</creator><creator>Mack, Michelle</creator><creator>Zhao, Xiao-Juan</creator><creator>Pride, Michael W</creator><creator>Andrew, Lubomira</creator><creator>Murphy, Ellen</creator><creator>Hagen, Michael</creator><creator>French, Roger</creator><creator>Arora, Ashoni</creator><creator>Jones, Thomas R</creator><creator>Jansen, Kathrin U</creator><creator>Zlotnick, Gary W</creator><creator>Anderson, Annaliesa S</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20100823</creationdate><title>Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease</title><author>Jiang, Han-Qing ; Hoiseth, Susan K ; Harris, Shannon L ; McNeil, Lisa K ; Zhu, Duzhang ; Tan, Cuiwen ; Scott, Adrienne A ; Alexander, Kristin ; Mason, Kathryn ; Miller, Lynn ; DaSilva, Ida ; Mack, Michelle ; Zhao, Xiao-Juan ; Pride, Michael W ; Andrew, Lubomira ; Murphy, Ellen ; Hagen, Michael ; French, Roger ; Arora, Ashoni ; Jones, Thomas R ; Jansen, Kathrin U ; Zlotnick, Gary W ; Anderson, Annaliesa S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-c6e8b4b3a6506112e14e186bb58530e31b6788233c6434a637ae45be5f5c35c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antigens, Bacterial - immunology</topic><topic>Applied microbiology</topic><topic>Bacterial Proteins - immunology</topic><topic>Biological and medical sciences</topic><topic>Colleges & universities</topic><topic>Female</topic><topic>fHBP</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>LP2086</topic><topic>Meningitis</topic><topic>Meningococcal Infections - immunology</topic><topic>Meningococcal Infections - prevention & control</topic><topic>Meningococcal Vaccines - immunology</topic><topic>Microbiology</topic><topic>Mortality</topic><topic>N. meningitidis serogroup B</topic><topic>Neisseria meningitidis</topic><topic>Neisseria meningitidis, Serogroup B - genetics</topic><topic>Neisseria meningitidis, Serogroup B - immunology</topic><topic>Proteins</topic><topic>Public health</topic><topic>Rabbits</topic><topic>Recombinant Proteins - immunology</topic><topic>Serum Bactericidal Test</topic><topic>Species Specificity</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Han-Qing</creatorcontrib><creatorcontrib>Hoiseth, Susan K</creatorcontrib><creatorcontrib>Harris, Shannon L</creatorcontrib><creatorcontrib>McNeil, Lisa K</creatorcontrib><creatorcontrib>Zhu, Duzhang</creatorcontrib><creatorcontrib>Tan, Cuiwen</creatorcontrib><creatorcontrib>Scott, Adrienne A</creatorcontrib><creatorcontrib>Alexander, Kristin</creatorcontrib><creatorcontrib>Mason, Kathryn</creatorcontrib><creatorcontrib>Miller, Lynn</creatorcontrib><creatorcontrib>DaSilva, Ida</creatorcontrib><creatorcontrib>Mack, Michelle</creatorcontrib><creatorcontrib>Zhao, Xiao-Juan</creatorcontrib><creatorcontrib>Pride, Michael W</creatorcontrib><creatorcontrib>Andrew, Lubomira</creatorcontrib><creatorcontrib>Murphy, Ellen</creatorcontrib><creatorcontrib>Hagen, Michael</creatorcontrib><creatorcontrib>French, Roger</creatorcontrib><creatorcontrib>Arora, Ashoni</creatorcontrib><creatorcontrib>Jones, Thomas R</creatorcontrib><creatorcontrib>Jansen, Kathrin U</creatorcontrib><creatorcontrib>Zlotnick, Gary W</creatorcontrib><creatorcontrib>Anderson, Annaliesa S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Han-Qing</au><au>Hoiseth, Susan K</au><au>Harris, Shannon L</au><au>McNeil, Lisa K</au><au>Zhu, Duzhang</au><au>Tan, Cuiwen</au><au>Scott, Adrienne A</au><au>Alexander, Kristin</au><au>Mason, Kathryn</au><au>Miller, Lynn</au><au>DaSilva, Ida</au><au>Mack, Michelle</au><au>Zhao, Xiao-Juan</au><au>Pride, Michael W</au><au>Andrew, Lubomira</au><au>Murphy, Ellen</au><au>Hagen, Michael</au><au>French, Roger</au><au>Arora, Ashoni</au><au>Jones, Thomas R</au><au>Jansen, Kathrin U</au><au>Zlotnick, Gary W</au><au>Anderson, Annaliesa S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2010-08-23</date><risdate>2010</risdate><volume>28</volume><issue>37</issue><spage>6086</spage><epage>6093</epage><pages>6086-6093</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein sequences segregate into two distinct subfamilies, designated A and B. Here, we report the specificity and vaccine potential of mono- or bivalent fHBP-containing vaccines. A bivalent fHBP vaccine composed of a member of each subfamily elicited substantially broader bactericidal activity against MnB strains expressing heterologous fHBP than did either of the monovalent vaccines. Bivalent rabbit immune sera tested in serum bactericidal antibody assays (SBAs) against a diverse panel of MnB clinical isolates killed 87 of the 100 isolates. Bivalent human immune sera killed 36 of 45 MnB isolates tested in SBAs. Factors such as fHBP protein variant, PorA subtype, or MLST were not predictive of whether the MnB strain could be killed by rabbit or human immune sera. Instead, the best predictor for killing in the SBA was the level of in vitro surface expression of fHBP. The bivalent fHBP vaccine candidate induced immune sera that killed MnB isolates representing the major MLST complexes, prevalent PorA subtypes, and fHBP variants that span the breadth of the fHBP phylogenetic tree. Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>20619376</pmid><doi>10.1016/j.vaccine.2010.06.083</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2010-08, Vol.28 (37), p.6086-6093 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_807267085 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Allergy and Immunology Animals Antibodies Antigens, Bacterial - immunology Applied microbiology Bacterial Proteins - immunology Biological and medical sciences Colleges & universities Female fHBP Fundamental and applied biological sciences. Psychology Humans LP2086 Meningitis Meningococcal Infections - immunology Meningococcal Infections - prevention & control Meningococcal Vaccines - immunology Microbiology Mortality N. meningitidis serogroup B Neisseria meningitidis Neisseria meningitidis, Serogroup B - genetics Neisseria meningitidis, Serogroup B - immunology Proteins Public health Rabbits Recombinant Proteins - immunology Serum Bactericidal Test Species Specificity Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) |
| title | Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T15%3A50%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Broad%20vaccine%20coverage%20predicted%20for%20a%20bivalent%20recombinant%20factor%20H%20binding%20protein%20based%20vaccine%20to%20prevent%20serogroup%20B%20meningococcal%20disease&rft.jtitle=Vaccine&rft.au=Jiang,%20Han-Qing&rft.date=2010-08-23&rft.volume=28&rft.issue=37&rft.spage=6086&rft.epage=6093&rft.pages=6086-6093&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2010.06.083&rft_dat=%3Cproquest_cross%3E807267085%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1497227037&rft_id=info:pmid/20619376&rft_els_id=S0264410X10009242&rfr_iscdi=true |